We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Auris (EARS) Begins Phase III Study for Sudden Deafness
Read MoreHide Full Article
Auris Medical Holding AG announced the commencement of patient enrollment in a second pivotal phase III study (ASSENT) on its pipeline candidate AM-111 for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL), which is also known as sudden deafness.
The randomized, double-blind, placebo-controlled study is being conducted to evaluate the efficacy, safety and tolerability of a single-dose intratympanic administration of AM-111 in patients suffering from severe-to-profound ISSNHL within 72 hours from onset.
We note that the first pivotal phase III study – HEALOS – on AM-111 is currently underway in several European and Asian countries. In addition, the company plans to conduct a phase II study (REACH) on the candidate for the treatment of surgery-induced hearing loss in the U.S.
We are encouraged by the company’s progress with AM-111. The candidate enjoys orphan drug status both in the U.S. and EU for the treatment of acute sensorineural hearing loss.
The company also has another candidate, Keyzilen, in a couple of phase III studies – TACTT2 and TACTT3 – for the treatment of acute inner ear tinnitus. While top-line data from TACTT2 are expected in Aug 2016, TACTT3 top-line results are expected in the fourth quarter of 2016.
We note that both acute inner ear tinnitus and hearing loss are conditions that represent significantly unmet medical need. Considering the lack of approved treatments targeting these conditions, both Keyzilen and AM-111 could become the first treatment to be approved for these indications, upon successful development and subsequent approval.
Auris is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Auris (EARS) Begins Phase III Study for Sudden Deafness
Auris Medical Holding AG announced the commencement of patient enrollment in a second pivotal phase III study (ASSENT) on its pipeline candidate AM-111 for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL), which is also known as sudden deafness.
The randomized, double-blind, placebo-controlled study is being conducted to evaluate the efficacy, safety and tolerability of a single-dose intratympanic administration of AM-111 in patients suffering from severe-to-profound ISSNHL within 72 hours from onset.
We note that the first pivotal phase III study – HEALOS – on AM-111 is currently underway in several European and Asian countries. In addition, the company plans to conduct a phase II study (REACH) on the candidate for the treatment of surgery-induced hearing loss in the U.S.
We are encouraged by the company’s progress with AM-111. The candidate enjoys orphan drug status both in the U.S. and EU for the treatment of acute sensorineural hearing loss.
The company also has another candidate, Keyzilen, in a couple of phase III studies – TACTT2 and TACTT3 – for the treatment of acute inner ear tinnitus. While top-line data from TACTT2 are expected in Aug 2016, TACTT3 top-line results are expected in the fourth quarter of 2016.
We note that both acute inner ear tinnitus and hearing loss are conditions that represent significantly unmet medical need. Considering the lack of approved treatments targeting these conditions, both Keyzilen and AM-111 could become the first treatment to be approved for these indications, upon successful development and subsequent approval.
Auris is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>